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The aim of the present study was to evaluate the effect of joint immobilization on morphometric parameters and glycogen content
of soleus muscle treated with clenbuterol. Male Wistar (3-4 months old) rats were divided into 4 groups (N = 6 for each group):
control, clenbuterol, immobilized, and immobilized treated with clenbuterol. Immobilization was performed with acrylic resin
orthoses and 10 µg/kg body weight clenbuterol was administered subcutaneously for 7 days. The following parameters were
measured the next day on soleus muscle: weight, glycogen content, cross-sectional area, and connective tissue content. The
clenbuterol group showed an increase in glycogen (81.6%, 0.38 ± 0.09 vs 0.69 ± 0.06 mg/100 g; P < 0.05) without alteration in
weight, cross-sectional area or connective tissue compared with the control group. The immobilized group showed a reduction
in muscle weight (34.2%, 123.5 ± 5.3 vs 81.3 ± 4.6 mg; P < 0.05), glycogen content (31.6%, 0.38 ± 0.09 vs 0.26 ± 0.05 mg/100
mg; P < 0.05) and cross-sectional area (44.1%, 2574.9 ± 560.2 vs 1438.1 ± 352.2 µm2; P < 0.05) and an increase in connective
tissue (216.5%, 8.82 ± 3.55 vs 27.92 ± 5.36%; P < 0.05). However, the immobilized + clenbuterol group showed an increase in
weight (15.9%; 81.3 ± 4.6 vs 94.2 ± 4.3 mg; P < 0.05), glycogen content (92.3%, 0.26 ± 0.05 vs 0.50 ± 0.17 mg/100 mg; P < 0.05),
and cross-sectional area (19.9%, 1438.1 ± 352.2 vs 1724.8 ± 365.5 µm2; P < 0.05) and a reduction in connective tissue (52.2%,
27.92 ± 5.36 vs 13.34 ± 6.86%; P < 0.05). Statistical analysis was performed using Kolmogorov-Smirnov and homoscedasticity
tests. For the muscle weight and muscle glycogen content, two-way ANOVA and the Tukey test were used. For the cross-
sectional area and connective tissue content, Kruskal-Wallis and Tukey tests were used. This study emphasizes the importance
of anabolic pharmacological protection during immobilization to minimize skeletal muscle alterations resulting from disuse.
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Introduction
Skeletal muscle function depends of many factors,
such as intact proprioceptive activity and innervation, me-
chanical load, and joint mobility (1-3). In many adverse
situations, such as injury of skeletal muscle, bone and
ligaments, immobilization is the most common method of
treatment (1-3). However, one of its most preeminent
effects is muscular atrophy (1-3). Several experimental
models have been proposed to identify the events initiated
by muscle disuse and the onset of precursors of atrophy,
which include denervation, tenotomy, prolonged bed rest,
hindlimb suspension, or unilateral immobilization (4). Mus-
cular disuse induces insulin resistance and a catabolic
state in human skeletal muscles (5) associated with a
decrease in GLUT4 transporters (6). Although it is fre-
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quently necessary, immobilization is accompanied by side
effects, such as muscular cell atrophy, intramuscular fibro-
sis, loss of muscle extensibility, and limitations in joint
motion (7). Several studies have demonstrated that con-
comitant with muscular hypotrophy, great modifications
occur in skeletal muscle homeostasis, affecting myofibril-
lar protein synthesis, contractile dynamics as well as the
effectiveness of metabolic signals, that can lead to a re-
duction in glycogen reserves, force and fatigue resistance
(4,8,9).
Clenbuterol is a β2-adrenoceptor agonist used as a
bronchodilator for treating lung diseases (10). It also has
an anabolic muscular effect and lipolytic activity (11). Low
doses of clenbuterol (10 µg/kg) minimize muscular atrophy
in rats, which is partially associated with denervation (12).
Other studies on rats also reported that low doses of
clenbuterol can cause anabolic effects without myocyte
death (13,14). Clenbuterol also presents anabolic effects
on the skeletal muscle of non-immobilized mice (15).
Therefore, the objective of the present study was to
evaluate the effect of low doses of clenbuterol on morpho-
metric and metabolic parameters of rat soleus muscles
submitted to joint immobilization for 7 days.
Material and Methods
All experimental procedures were approved by the
Ethics Committee for Experimental Research of the Uni-
versity Federal de São Carlos (#03/06).
Male Wistar rats (3-4 months old; 250-300 g) were
maintained under controlled conditions of temperature and
humidity, with free access to food and water. The animals
were divided into 4 groups (N = 6 for each group): control,
non-immobilized clenbuterol, immobilized, and immobi-
lized treated with clenbuterol for 7 days.
The rats were anesthetized (intraperitoneal injection of
sodium pentobarbital, 50 mg/kg body weight) and the left
hindlimb was immobilized in neutral ankle position with
acrylic resin orthoses (8). Clenbuterol (10 µg/kg body
weight) was administered subcutaneously daily at 9:00 am
(6). After 7 days, the animals were killed and the soleus
muscle was isolated and weighed by analytic scale and
divided for analysis of glycogen content, cross-sectional
area and connective tissue content.
The muscle extremities were used for analysis of gly-
cogen content. Samples were digested in KOH, the glyco-
gen was precipitated with ethanol, centrifuged and submit-
ted to acid hydrolysis in the presence of phenol and meas-
ured according to Lo et al. (16).
The soleus belly was processed in paraffin and 5 non-
serial 7-µm thick cross-sections were obtained and stained
with hematoxylin-eosin for morphometric analysis. Image
analysis system was carried out with the Image Pro-plus
4.0 software (Media Cybernects, USA), a digital camera
(JVC, USA) coupled to a microscope (Zeiss, Germany),
and connected to a computer. All images were captured at
100X magnification and analyzed as described (8). Cross-
sectional area measurements were made on 375 myofibers
from 5 fields on each of the 5 muscle sections. A planimetry
system was used for intramuscular connective tissue anal-
ysis, by the method of Weibel (17) and the density (%) was
calculated.
The statistical analysis was performed by Kolmogorov-
Smirnov and homoscedasticity tests. For the muscle weight
and muscle glycogen content, two-way ANOVA (factors:
immobilization x treatment) and the Tukey test were used.
For the cross-sectional area and connective tissue con-
tent, Kruskal-Wallis and Tukey tests were used (P < 0.05).
Results
The clenbuterol-treated group presented higher soleus
glycogen (81.6%, P < 0.05) without alterations in weight,
cross-sectional area and connective tissue compared with
the control group (Table 1, Figure 1A and B).
Rats immobilized for 7 days had 34.2% less soleus
muscle weight and 31.6% less glycogen content (Table 1)
compared with the control group (P < 0.05). The cross-
Table 1. Effect of clenbuterol on atrophy caused by immobilization of soleus muscle in the rat.
C Cle I I + Cle
Weight (mg) 123.5 ± 5.3 128.1 ± 5.05 81.3 ± 4.6* 94.2 ± 4.3*+
Glycogen (mg/100 mg) 0.38 ± 0.09 0.69 ± 0.06* 0.26 ± 0.05* 0.50 ± 0.17+
Fiber area (µm2) 2574.9 ± 560.2 2531.7 ± 636.8 1438.1 ± 352.2* 1724.8 ± 365.5*#+
Connective tissue (%) 8.82 ± 3.55 8.99 ± 4.19 27.92 ± 5.36* 13.34 ± 6.86*#+
Data are reported as mean ± SD (N = 6). C = control; Cle = clenbuterol treatment for 7 days; I = immobilized for
7 days; I + Cle = immobilized for 7 days with clenbuterol treatment. *P < 0.05, compared with C group; +P < 0.05,
compared with I group; #P < 0.05, compared with Cle group.
1056
Braz J Med Biol Res 41(12) 2008
K.M. Cancelliero et al.
www.bjournal.com.br
sectional area of soleus muscle was 44.1% less and there
was 216.5% more connective tissue (from 8.82 ± 3.55 to
27.92 ± 5.36%) compared with the control group (P < 0.05,
Table 1, Figure 1C).
When the immobilized group was compared with the
immobilized + clenbuterol group, it is clear that the clen-
buterol-treated rats had higher muscle weight (15.9%,
from 81.3 ± 4.6 to 94.2 ± 4.3 mg), and glycogen content
(92.3%, from 0.26 ± 0.05 to 0.50 ± 0.17 mg/100 mg; P <
0.05; Table 1).
When the clenbuterol group was compared with the
immobilized + clenbuterol group, greater cross-sectional
area (19.9%, P < 0.05) and less connective tissue (52.2%,
P < 0.05) were observed with clenbuterol (Table 1; Figure
1B and D). Thus, although the clenbuterol treatment in-
creased the cross-sectional area in immobilized animals, it
did not revert completely the decrease caused by immobi-
lization, with a significant difference between these groups
(P < 0.05). Clenbuterol treatment in the immobilized group
inhibited connective tissue accumulation compared with
non-clenbuterol-treated animals (P < 0.05, Figure 1D);
however, it did not inhibit completely the connective tissue
accumulation at control levels.
When the control group was compared with immobi-
lized + clenbuterol (10 µg/kg), no difference in glycogen
content was found; however, there was a decrease of
23.7% (P < 0.05) in weight, this value being lower than that
of the immobilized group. The cross-sectional area and
connective tissue also presented significant differences (P
< 0.05, Figure 1A and D).
Discussion
As far as we know, this is the first study that analyzed
the effects of a low dose of clenbuterol in a disuse muscle
model. Data analysis revealed that clenbuterol prevents
muscle loss in soleus muscle, including muscle weight,
muscle glycogen content and cross-sectional area of fi-
bers, which could be beneficial in cachexia and disuse
conditions.
Selective agonists of β-adrenoceptors, such as clen-
buterol, may counter hypotrophy by disuse because of their
anabolic effects. However, the mechanisms by which β-
adrenergic agents induce anabolism are still not fully under-
stood (18,19). Fitton et al. (6) reported that low doses of
clenbuterol have a protective effect on denervated muscle
Figure 1. Soleus muscle fibers stained with hematoxylin and eosin. A, Control group. B, Clenbuterol treatment for 7 days. C,
Immobilized in ankle neutral position for 7 days. A reduction of muscle fiber area (asterisk) and an increase of intramuscular
connective tissue (arrow) can be seen compared with the control group. D, Immobilized and clenbuterol treatment for 7 days. An
increase of muscle fiber area (asterisk) and a decrease of intramuscular connective tissue (arrow) can be seen compared with the
immobilized group. Original magnification: 100X.
50 µm 50 µm
50 µm 50 µm
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before its reinnervation, reducing protein loss and muscular
fiber atrophy and partially preserving contractile performance.
The results of the present study demonstrated the
anabolic effects of low doses of clenbuterol under condi-
tions of disuse, i.e., prevented loss of soleus weight and
cross-sectional area. This correlates with the Canu et al.
study (20), in which the anabolic action of clenbuterol was
observed in both normal and atrophied muscles. Pellegrino
et al. (21) also observed increased cross-sectional area of
mouse soleus muscle in the presence of clenbuterol.
Akatsu et al. (18) reported that regulatory mechanisms
for skeletal muscle hypertrophy by clenbuterol are unclear;
however, they suggest that transforming growth factor β
could be involved. Matsumoto et al. (22) suggested that
one hypothesis to explain the skeletal muscle hypertrophy
induced by clenbuterol is the stimulated production of
peptide growth factors such as insulin-like growth factors.
However, these studies differ in regard to doses, including
low and large doses. Chen and Alway (13) observed that
the administration of clenbuterol at 10 µg/kg body weight
reduced atrophy in the slow muscle of senescent rats.
Burniston et al. (14) observed that 1 mg/kg clenbuterol
increased the protein content associated with myofiber
hypertrophy.
Despite glycogen utilization, the immobilized group
presented glycogen reduction. Bevan (23) showed that
insulin acts in different ways, and that there is participation
by subunit PI3-K (phosphatidylinositol 3-kinase), which is
responsible for several mechanisms including glycogen
synthesis. Muscular disuse induces insulin resistance and
a catabolic state in human skeletal muscles (5). In rat
hindlimbs immobilized for 7 days, Hirose et al. (24) ob-
served a reduction in intracellular signaling stimulated by
insulin and in glucose uptake, suggesting deficit in PI3-K
activation, which could explain the results of decrease
glycogen in this study; this being one of the mechanisms
activated by PI3-K subunit. In the present study, glycogen
was increased in clenbuterol and immobilized + clen-
buterol groups, which could be explained by clenbuterol
causing an increase in tissue glucose uptake, possibly
because of the permissive effect of insulin action (25,26).
Pan et al. (26) observed that the increased glucose uptake
stimulated by clenbuterol was parallel to the increase in
glycogen reserves. According to Hunt et al. (27), the pos-
sibility of increased insulin sensitivity in the skeletal muscle
after clenbuterol treatment could be due to the reduced
influence of epinephrine on insulin action as a result of
down-regulation of β-adrenergic receptors.
The connective tissue area density values were lower
in the immobilized + clenbuterol group compared with the
immobilized group. Because clenbuterol has an anabolic
action, an increase in protein synthesis of the extracellular
matrix was also expected (28). As this was not observed, it
may be that differences in rate of renewal among intramus-
cular proteins and extracellular matrix might have influ-
enced the results. Because collagen proteins have a slower
rate of renewal than muscular tissue (29), clenbuterol did
not increase the cross-sectional area (19.9%) as intensely
as it decreased the connective tissue (52.2%) in the immo-
bilized + clenbuterol group. This finding is related to a
study by Jiang et al. (30), in which the authors observed
that clenbuterol (60 µg for more than 3 months) minimized
collagen proliferation in denervated skeletal muscle of
humans. An important fact in the present study is that the
clenbuterol treatment for 7 days led to a decrease in
connective tissue using a dose six times smaller than the
dose used by Jiang et al. (30).
In contrast, in the study of Patiyal and Katoch (31), high
doses of clenbuterol (2 mg/kg) caused collagen content
proliferation in the mouse gastrocnemius due to the ana-
bolic effect on protein of clenbuterol in the skeletal muscle.
In the Burniston study (14), there was myocyte death and
collagen increase in myocardium (100 µg/kg or 1 mg/kg).
Along these lines, collagen proliferation seems to be re-
lated to the dose administered since the present study
demonstrated that low doses of clenbuterol for a short
period induced connective tissue reduction in soleus muscle
during 7 days of joint immobilization.
In conclusion, we found that 10 µg/kg clenbuterol, sc,
for a short period of time was efficient in minimizing reduc-
tion of muscle weight, fiber area and glycogen content
during joint immobilization. The extrapolation of our results
to clinical practice would suggest that low doses of clen-
buterol could be useful during muscle disuse periods, i.e.,
in joint immobilization before rehabilitation.
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